The FDA has granted Flamel Technologies approval for its new drug application for Bloxiverz. The drug is used to reverse the effects of non-depolarizing neuromuscular blocking agents following surgery.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||